Formosa Journal of Multidisciplinary Research (FJMR)
Vol. 4 No. 10, 2025: 4973-4990

Current Approaches to the Etiology, Prevention, Diagnosis and Treatment of Nephrolithiasis: A Review of Recent Literature

Habibi Hibatullah
General Practioner, Puskesmas Iboih Sabang, Indonesia
Corresponding Author: Habibi Hibatullah habibi.pidie@gmail.com

A R T I C L E I N F O

Keywords: Etiology, Prevention, Diagnosis, and Treatment of Nephrolithiasis

Received : 16, September
Revised : 30, September
Accepted: 23, October

A B S T R A C T

Nephrolithiasis is a multifactorial disease arising from the interaction of biochemical, metabolic, genetic, environmental, and lifestyle factors. Urinary supersaturation with calcium, oxalate, phosphate, or uric acid promotes crystal nucleation, growth, and aggregation, while imbalances in natural inhibitors (e.g., citrate, magnesium) as well as epithelial injury and oxidative stress enhance crystal retention. Metabolic abnormalities such as hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria often underlie stone formation; in children, the contribution of hereditary disorders is more prominent. Prevention emphasizes increased hydration (target urine output ≈2–2.5 L/day), adequate dietary calcium with sodium and animal protein restriction, increased fruit and vegetable consumption to increase urinary citrate, and population education, which has proven cost-effective. Diagnosis integrates history, urinalysis, and metabolic evaluation (24-hour urine collection), and imaging—ultrasound as the initial modality in selected situations, with non-contrast CT as the gold standard when necessary. Acute management includes analgesia, hydration, and medical expelling therapy for small stones; minimally invasive interventions—ESWL, ureteroscopy, or PNL—are chosen based on stone size/location and clinical condition. Preventive pharmacological therapy is tailored to the metabolic abnormality (thiazides, potassium citrate, allopurinol) and combined with dietary modification and regular follow-up to suppress recurrence and improve long-term renal outcomes.

DOI: https://doi.org/10.55927/fjmr.v4i10.554
ISSN-E: 2829-8896
https://npaformosapublisher.org/index.php/fjmr

INTRODUCTION

Nephrolithiasis, or kidney stones, is a complex disorder that arises from the interaction of biochemical, genetic, and environmental factors. This condition is characterized by the formation of stones in the urinary tract due to urine supersaturation with lithogenic substances such as calcium, oxalate, phosphate, or uric acid, which then undergo nucleation and aggregation. An imbalance between crystallization promoters and inhibitors—such as citrate, magnesium, nephrocalcin, and Tamm-Horsfall protein—is the primary basis for this process. Renal epithelial injury and oxidative stress enhance crystal retention, making nephrolithiasis not only a mechanical process but also a biological one involving renal cellular responses.

Metabolically, several disorders such as hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria play a significant role in stone formation. These disorders can be isolated or interconnected through genetic mechanisms, dietary patterns, or systemic metabolic conditions. Hypercalciuria increases urinary calcium excretion and promotes crystallization, while hypocitraturia decreases the urine's ability to inhibit nucleation. Conversely, hyperuricosuria can accelerate uric acid stone formation and act as a heterogeneous nucleus for calcium oxalate stones.

Diet and lifestyle factors also play a significant role. Low fluid intake leads to concentrated urine, increasing the risk of supersaturation with lithogenic substances. Diets high in animal protein and sodium increase calcium and uric acid excretion, while low-calcium diets actually increase oxalate absorption. Conversely, a balanced diet with adequate calcium intake, low sodium intake, and increased fruit and vegetable consumption has been shown to reduce recurrence.

Pathophysiologically, Randall's plaque hypothesis explains the role of subepithelial calcium phosphate deposition in the renal papillae as the initial site of stone attachment. This finding is complemented by the free and fixed particle theory, which describes intratubular precipitation or crystal adhesion to damaged epithelium. At the microscopic level, oxidative stress and local inflammation have been shown to exacerbate tubular injury and promote stone formation.

In children, the same etiologic mechanisms are found, but hereditary factors such as cystinuria or primary hyperoxaluria are more often the underlying cause. The increase in cases in healthy children is also associated with a high-sodium, low-fluid diet that mimics the lifestyle of adults.

Nephrolithiasis is a multifactorial disease that reflects a balance between urine biochemistry, metabolic status, and renal epithelial integrity. A comprehensive understanding of these aspects is essential for effective diagnosis, prevention, and management.

LITERATURE REVIEW

Etiology

Nephrolithiasis, or kidney stone disease, is a multifactorial disorder arising from a complex interaction between urinary supersaturation, crystal nucleation,

growth, aggregation, and retention in the renal tubules. Its etiology lies primarily in an imbalance between substances that promote stone formation—such as calcium, oxalate, uric acid, and phosphate—and crystallization inhibitors, such as citrate, magnesium, nephrocalcin, Tamm-Horsfall protein, osteopontin, and glycosaminoglycans. Urinary supersaturation with lithogenic saline promotes the formation of crystals that can adhere to the renal epithelial surface and serve as a nidus for stone growth. Local epithelial injury and oxidative stress further facilitate crystal attachment and retention, thus enhancing stone formation. This multifactorial cascade confirms that nephrolithiasis is rooted in both systemic and local biochemical origins, rather than a single causal pathway.



Figure 1. Pathogenesis of Nephrolithiasis[11]

Several metabolic and biochemical abnormalities contribute to stone formation. Hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria are the most common urinary disorders found in patients with kidney stones. Hypercalciuria—whether absorptive, resorptive, or renal—causes increased

urinary calcium excretion and precipitation of calcium-based crystals. Elevated urinary oxalate levels, whether idiopathic or secondary to enteric disorders, significantly increase the risk of calcium oxalate stone formation due to the strong lithogenic properties of oxalate even at low concentrations. Hypocitraturia reduces the ability of urine to inhibit calcium crystal nucleation, while hyperuricosuria contributes to uric acid stones and can act as a heterogeneous nucleator for calcium oxalate stones. These abnormalities are often interrelated and are influenced by diet, genetic predisposition, and systemic metabolic conditions.

COMPOSITION	FREQUENCY	CAUSES AND MECHANISMS
Calcium oxalate or calcium phosphate	70%–80%	Hypercalciuria High dietary sodium and protein intake Hypercalcemia Idiopathic Chronic metabolic acidosis Low urine volume Chronic dehydration, hot climate with increased water loss Hyperuricosuria High-purine, high-protein diet Gout Hyperoxaluria Low dietary calcium, high-oxalate diet, genetic hyperoxaluria Low urine citrate Chronic metabolic acidosis Renal tubular acidosis Inflammatory bowel disease Idiopathic
Uric acid	10%–15%	Low urine pH, defect in renal ammonium secretion Chronic metabolic acidosis Hyperuricosuria Obesity, metabolic syndrome
Magnesium ammonium phosphate (struvite, infection-related)	10%–15%	Urine infection (urea-splitting bacteria)
Cystine	< 1%	Cystinuria Autosomal recessive disorder of cystine, ornithine, arginine, and lysine
Others	< 1%	
Indinavir (Crixivan)		Indinavir is an antiretroviral therapy for HIV
Triamterene (Dyrenium)		Triamterene is a potassium-sparing diuretic used to treat hypertension
Xanthine		Xanthine oxidase inhibitor therapy, eg, allopurinol (Zyloprim), for hyperuricemia or gout

Figure 2. Stone Composition, Incidence Rate and Causes

Environmental and dietary factors play a significant role in the pathogenesis of nephrolithiasis. Low fluid intake, resulting in concentrated urine, is a major determinant of stone risk by increasing supersaturation of lithogenic substances. Diets high in animal protein and sodium increase urinary calcium and uric acid excretion, while low calcium intake increases intestinal oxalate absorption and urinary oxalate levels. Conversely, adequate calcium intake with sodium and animal protein restriction has been shown to significantly reduce stone recurrence. Excessive consumption of high-oxalate foods, combined with inadequate magnesium and citrate intake, further increases the risk. These lifestyle factors highlight the preventable component of nephrolithiasis, for which dietary modification and hydration remain the cornerstones of management.

In addition to metabolic and dietary factors, specific systemic disorders and pathophysiological mechanisms also underlie specific stone types. For example, uric acid nephrolithiasis is primarily caused by persistently acidic urine, often associated with insulin resistance and metabolic syndrome. Low urine pH—not hyperuricosuria per se—promotes uric acid crystallization. Conversely, infectious stones, typically composed of struvite (magnesium ammonium phosphate), are caused by urease-producing bacteria that alkalinize the urine and induce precipitation of saline phosphate. Cystine stones result from a genetic defect in dibasic amino acid transport, leading to high urinary cystine levels. This variety of etiologies demonstrates that nephrolithiasis is not a single disease, but rather a manifestation of multiple biochemical and systemic abnormalities.



Figure 3. Schematic representation of the causes of uric acid nephrolithiasis.

Three main categories are shown. Some etiologies can be classified into more than one category. For example, primary gout syndrome clearly has a genetic component, but is currently considered an idiopathic syndrome. Patients with gouty diathesis overlap with those with metabolic syndrome, and both share common characteristics of urinary chemistry abnormalities that facilitate the formation of uric acid kidney stones (uric acid nephrolithiasis).



Calcium oxalate dihydrate

Calcium oxalate monohydrate



Figure 4. Characteristics of Kidney Stones: Calcium Oxalate, Calcium Phosphate and Uric Acid

At the cellular level, various studies highlight the importance of epithelial injury and interstitial deposition in the initiation of stone formation. Randall's plaque hypothesis describes subepithelial deposits of calcium phosphate in the renal papillae that serve as attachment sites for overlying calcium oxalate stones. Alternative theories, such as the free particle and fixed particle hypotheses, emphasize intratubular crystal precipitation or adhesion to damaged epithelial surfaces. Microscopic evidence suggests that oxidative stress, reactive oxygen species, and local inflammation exacerbate tubular injury, facilitating crystal attachment and retention. Thus, nephrolithiasis is both a physicochemical and a biological process that integrates urine chemistry with renal epithelial pathophysiology.



Figure 5. Schematic representation of various intracellular and extracellular events during the stone formation process. ∗(OPN: osteopontin, HA: hyaluronic acid, SA: sialic acid, MCP-1: monocyte chemoattractant protein-1).

In the pediatric population, nephrolithiasis shares similar etiological mechanisms but more often reflects hereditary or metabolic disorders rather than lifestyle factors. Children may present with conditions such as cystinuria, distal renal tubular acidosis, or primary hyperoxaluria. However, the increased incidence in healthy children is associated with modern dietary patterns—high in sodium, high in animal protein, and low in fluid intake—that resemble adult patterns. Diagnostic evaluation in pediatric cases emphasizes metabolic assessment and efforts to minimize radiation exposure during imaging.

The etiology of nephrolithiasis encompasses a broad spectrum of interacting biochemical, dietary, genetic, and environmental factors. This multifaceted nature demands a comprehensive understanding of systemic metabolic influences, urinary biochemistry, and renal cellular physiology.

Advances in molecular and clinical research have shifted the view of nephrolithiasis from a mechanical process of crystal precipitation to a complex systemic disease reflecting overall metabolic health.

METHODOLOGY

This study employed a qualitative descriptive literature review method to analyze the current approaches in the etiology, prevention, diagnosis, and treatment of nephrolithiasis. Data were obtained from various scientific sources, including reputable international journals, clinical guidelines, and relevant epidemiological studies published within the last two decades. Literature was collected through online databases using keywords such as *nephrolithiasis, etiology, prevention, diagnosis,* and *treatment.* Each publication was selected based on its relevance to the topic, methodological validity, and contribution to understanding the biochemical mechanisms and clinical management of kidney stones. The findings from these sources were then compared and synthesized to identify patterns, differences, and recent developments, aiming to provide a comprehensive scientific overview that supports both clinical practice and future research.

RESEARCH RESULT AND DISCUSSION

Prevention

Prevention of nephrolithiasis focuses on reducing urine supersaturation with lithogenic saline through dietary modification, increased hydration, and targeted pharmacological interventions. Adequate fluid intake is the cornerstone of both primary and secondary prevention, as increased urine volume dilutes stone-forming substances and decreases crystal aggregation. Studies have shown that maintaining urine output at least 2–2.5 L per day significantly reduces the rate of stone recurrence. This preventive measure is simple, cost-effective, and applicable to all stone patients, regardless of stone composition. Epidemiological and clinical studies also support that increased water intake reduces stone risk, while inadequate hydration remains the primary cause of recurrence.

Dietary modification is another important aspect of prevention. A diet with adequate calcium intake, sodium restriction, and reduction in animal protein has been shown to reduce the risk of recurrence, especially for calcium-containing stones. Contrary to previous beliefs, a low-calcium diet can actually increase urinary oxalate levels and promote stone formation, whereas a normal calcium intake binds oxalate in the intestine and decreases its absorption. Therefore, patients are advised to maintain a normal calcium intake while limiting sodium and animal protein to reduce urinary calcium and uric acid excretion. Increasing fruit and vegetable consumption provides an alkalizing diet that increases urinary citrate levels—a natural inhibitor of stone formation. Conversely, a diet high in animal protein and sodium increases the urinary acid load, lowering citrate levels, and facilitating crystal precipitation.

Pharmacological therapy is indicated for patients with specific metabolic abnormalities identified through 24-hour urine analysis. Thiazide diuretics are effective in patients with hypercalciuria because they decrease urinary calcium

excretion and prevent calcium stone recurrence. Potassium citrate or other alkali preparations are used to correct hypocitraturia and alkalinize the urine in cases of uric acid or cystine stones. Allopurinol is indicated for hyperuricosuria and uric acid stones because it lowers serum and urinary uric acid levels. These targeted interventions, when combined with dietary modification, provide a comprehensive strategy for secondary prevention. Therapy compliance and continued metabolic evaluation are essential to maintain urinary chemistry balance and prevent recurrence.

Lifestyle modifications also contribute significantly to kidney stone prevention. Limiting high-oxalate foods such as spinach, nuts, and tea can reduce the oxalate burden in susceptible individuals, especially those with enteric hyperoxaluria. Patients are advised to avoid excessive consumption of sweetened beverages and limit alcohol consumption, while moderate consumption of coffee, tea, and wine is associated with a lower risk of stones. Physical activity and weight control are also important, as obesity and metabolic syndrome have been identified as risk factors for nephrolithiasis. Preventive measures should be individualized based on the patient's stone composition, metabolic profile, dietary patterns, and comorbidities.

From a public health perspective, population-level prevention strategies have proven cost-effective. Simulation models suggest that widespread increases in fluid intake could reduce the incidence of nephrolithiasis and generate significant savings for the health system. For example, population-based initiatives to promote hydration could prevent thousands of new cases each year while reducing health care costs. Education about dietary balance, adequate hydration, and early metabolic assessment could provide sustainable prevention measures at both the individual and community levels.

In pediatric nephrolithiasis, prevention principles are similar but must be carefully tailored to reduce recurrence without excessive dietary restriction. Increasing fluid intake remains the most important step, along with a balanced diet with normal calcium and low sodium intake. Because many pediatric cases are associated with inherited metabolic disorders, a thorough metabolic evaluation and individualized therapy are essential. Early prevention not only reduces recurrence but also prevents long-term kidney complications.

Prevention of nephrolithiasis requires a multifactorial and personalized approach that integrates hydration, dietary modification, metabolic correction, and patient education. The combination of behavioral changes with targeted pharmacological therapy has been shown to significantly reduce recurrence rates and improve quality of life in patients with recurrent stones. Continuous follow-up and patient compliance remain essential for the long-term success of stone prevention.

Diagnosis

The diagnosis of nephrolithiasis involves a combination of clinical evaluation, laboratory tests, and imaging to confirm the presence of urinary tract stones, identify their composition, and determine the underlying metabolic abnormalities. Initial assessment begins with a careful history and physical

examination, focusing on typical symptoms such as flank pain, hematuria, dysuria, or urinary tract obstruction. emphasize that the history should include a history of previous stones, family history, dietary habits, and fluid intake. Laboratory tests typically include urinalysis to detect microscopic hematuria, infection, or crystal type, and a 24-hour urine collection to assess the excretion of calcium, oxalate, uric acid, citrate, and other metabolites after the acute phase, ideally 4–6 weeks after the event to reflect baseline metabolism.



Figure 6. A proposed algorithm for imaging studies in patients with acute stone disease in the emergency department (ED)

Initial stratification is based on age; American Urological Association (AUA) guidelines specify that patients <14 years of age are categorized as pediatric. Adult patients are then stratified based on pregnancy status and body mass index (BMI). Ultrasonography should also be considered as an initial investigation in adult patients, particularly in those with a normal BMI and in adults with a strong clinical suspicion of urinary stone disease. In such cases, the sensitivity and specificity of ultrasonography are high enough to increase the pretest probability of a kidney stone without significantly increasing the risk of

missing an alternative diagnosis. Low-dose CT, i.e., CT without contrast with a radiation exposure of <3 mSv, may be considered as a subsequent option.

Imaging studies play a key role in establishing the diagnosis and determining treatment. Ultrasonography (USG) is the initial modality of choice, especially in pediatric and pregnant patients, due to its safety and radiation-free nature. However, if the ultrasound does not show stones or the findings are inconclusive, computed tomography (CT) of the abdomen and pelvis without contrast is necessary. stated that CT without contrast has become the gold standard for detecting all types and locations of stones, with higher sensitivity and specificity than intravenous urography (IVU) or plain radiography. CT allows for accurate determination of the size, density, and degree of anatomical obstruction, which is essential for planning treatment such as conservative therapy, extracorporeal shock wave lithotripsy (ESWL), or percutaneous nephrolithotomy (PNL).



Figure 7.Coronal view of bilateral nephrolithiasis measuring 8 mm on non-contrast CT. The stone is clearly visible using this imaging modality. Additional anatomic detail can be obtained by reconstructing the image in the axial plane. a. This coronal CT image clearly shows an obstructive stone on the left side. b. The posterior coronal CT view from panel a shows a non-obstructive stone at the lower pole of the kidney. An excellent level of anatomic detail is seen in these images and can be further enhanced by image reconstruction in the axial plane.

In addition to imaging, biochemical evaluation is essential for identifying metabolic causes of stone formation and designing preventive therapy. explains that a comprehensive metabolic evaluation includes measuring serum calcium, phosphate, uric acid, bicarbonate, and parathyroid hormone levels to rule out

systemic disorders such as hyperparathyroidism or renal tubular acidosis. A 24-hour urine test is recommended to measure calcium, oxalate, uric acid, citrate, sodium, and creatinine concentrations, which helps classify patients as hypercalciuria, hyperuricosuria, hypocitraturia, or hyperoxaluria. These findings allow for tailoring of dietary and pharmacological interventions, such as administering a thiazide diuretic for hypercalciuria, potassium citrate for hypocitraturia, or allopurinol for hyperuricosuria.

In some cases, diagnosis goes beyond detection and includes characterization of the stone type and associated systemic factors. He explained that nephrolithiasis should be viewed as a systemic disease often associated with metabolic syndrome, obesity, and insulin resistance. These factors affect urine composition and pH and increase the risk of uric acid and calcium oxalate stones. He added that further metabolic testing, such as genetic testing for primary hyperoxaluria or evaluation of enteric causes in patients with hyperoxaluria, may be considered in recurrent or severe cases. A thorough metabolic evaluation is crucial for preventing recurrence by targeting the underlying biochemical abnormalities, rather than simply removing the stones.

The diagnostic approach to nephrolithiasis is multimodal—integrating clinical history, laboratory analysis, and imaging—to confirm the presence of stones and to identify contributing metabolic conditions. The shift toward individualized evaluation, as demonstrated by recent studies, reflects the understanding that nephrolithiasis is not a single entity but rather a manifestation of systemic and metabolic disorders. Early and accurate diagnosis allows for targeted intervention, reduces recurrence, and improves long-term renal outcomes.

Therapy

Management of nephrolithiasis depends on the size, composition, and location of the stone, as well as accompanying clinical manifestations such as pain, obstruction, and infection. The initial approach focuses on relieving acute symptoms, facilitating spontaneous passage of small stones, and preventing complications. Conservative management is appropriate for stones <4 mm in diameter, as up to 80% of them pass spontaneously. Adequate hydration, analgesia, and medical expulsion therapy using alpha-blockers such as tamsulosin can aid stone passage. For stones 4–8 mm in size, close monitoring is necessary, while stones >8 mm or those causing severe obstruction or infection usually require intervention. The decision to intervene also takes into account patient factors such as a solitary kidney, pregnancy, or persistent pain. Therefore, initial management focuses on stabilization and pain control while assessing the need for procedural intervention.



Figure 8.Complex Kidney Stones



Figure 9. Management of Acute Nephrolithiasis

If spontaneous passage fails or the stone burden is large, various interventional procedures can be performed. outlines the main surgical options, including extracorporeal shock wave lithotripsy (ESWL), ureteroscopy (URS), percutaneous nephrolithotomy (PNL), and—rarely—open surgery. ESWL is the first-line therapy for small to medium-sized stones, with a success rate of 70–90%. Ureteroscopy is preferred for distal ureteral stones or stones resistant to ESWL because it allows direct visualization and fragmentation with a laser or

pneumatic device. PNL is indicated for large stones (>2.5 cm), staghorn calculi, or when ESWL and URS are unsuccessful. Open surgery is now performed in <2% of cases, usually for anatomic abnormalities or complex stone burdens. The development of minimally invasive techniques has increased stone-free rates while decreasing complications and length of stay.[17]

Pharmacological therapy plays a crucial role in both the acute phase and long-term prevention of stone recurrence. emphasize that drug therapy is tailored to the patient's specific metabolic abnormalities. Thiazide diuretics are given in hypercalciuria to decrease urinary calcium excretion, while potassium citrate is used to correct hypocitraturia and alkalinize the urine. Allopurinol is recommended for patients with hyperuricosuria or uric acid stones. Furthermore, dietary modification—reducing sodium, animal protein, and oxalate while maintaining normal calcium intake—is a key pillar of recurrence prevention. The cornerstone of therapy for all stone types remains high hydration with a target urine volume of ≥2–2.5 L per day to reduce urinary supersaturation with stone-forming saline.

Reinforced the principles of drug therapy by demonstrating that a normal-calcium, low-protein, and low-saline diet is more effective than a low-calcium diet in preventing calcium stone recurrence. Pharmacological options such as thiazides, indapamide, and potassium–magnesium citrate have been shown to reduce the risk of recurrence. Thiazides reduce hypercalciuria, while potassium–magnesium citrate supplementation not only alkalizes the urine but also increases citrate—an important inhibitor of calcium crystal aggregation. For uric acid stones, alkalinization of the urine with potassium citrate or sodium bicarbonate is the mainstay of treatment, while cystine stones require thiol-binding agents such as tiopronin or penicillamine. Borghi et al. also highlighted the role of acetohydroxamic acid in infection-associated struvite stones via urease activity inhibitors. An individualized therapeutic approach based on stone type and underlying metabolic disorder remains the gold standard for long-term disease management.[5]

In the pediatric population, the recommended stepwise management is the same as for adults, but with an emphasis on minimizing radiation exposure and invasive procedures. Ultrasonography is used to monitor treatment outcomes, and ESWL is considered safe and effective for stones <2 cm. For large or complex stones, percutaneous or endoscopic procedures are performed in specialized centers. Long-term follow-up with regular metabolic evaluation and dietary counseling is essential to prevent recurrence, as children often have underlying metabolic or anatomical abnormalities that contribute to stone formation.



Figure 10. Image sequence showing coronal sections on MRI.

a, b Images obtained using a T2-weighted sequence and c, d Images obtained using a T1-weighted sequence clearly demonstrate hydronephrosis, but

distal pathology is not evident. The scan was performed for cancer surveillance—the differential diagnosis included metastasis, external ureteral compression, and stones. e–g CT images demonstrate hydronephrosis and hydroureter; the right distal ureteral stone is now clearly visible, allowing for a correct diagnosis and significantly altering this patient's treatment plan.

Management of nephrolithiasis involves a combination of acute management, minimally invasive interventions, and drug therapy tailored to address the underlying metabolic abnormalities. Integration of dietary modification, pharmacological prevention, and advanced surgical techniques significantly reduces morbidity and recurrence rates. Successful management requires individualized evaluation based on stone composition, patient characteristics, and risk factors, highlighting the importance of a multidisciplinary approach involving urology and metabolic evaluation.[1,5,10,17]

CONCLUSIONS AND RECOMMENDATIONS

Nephrolithiasis is the result of a complex interaction between metabolic, biochemical, dietary, and genetic factors that lead to crystal precipitation in the urinary system. An imbalance between stone-forming substances such as calcium and oxalate and natural inhibitors such as citrate and magnesium underlies the pathogenesis. Urinary supersaturation, renal epithelial injury, and oxidative stress enhance crystal retention and support stone formation. Conversely, hypercalciuria, hyperoxaluria, hypocitraturia, and lifestyle factors—such as low fluid intake and a diet high in animal protein—play a significant role in the risk of recurrence.

Current approaches to the prevention and management of nephrolithiasis emphasize dietary modification, optimal hydration, and correction of metabolic disorders through pharmacological therapy. Minimally invasive interventions such as ESWL, ureteroscopy, or PNL are used in cases that cannot be managed conservatively. A comprehensive metabolic evaluation allows for individualized therapy based on stone type and cause, thereby reducing recurrence rates and improving long-term renal outcomes. A multidisciplinary approach integrating biochemical, clinical, and lifestyle aspects is essential for successful nephrolithiasis management.

ADVANCED RESEARCH

Future research on nephrolithiasis should advance toward an integrative precision medicine approach that combines genomic, metabolomic, and microbiome profiling to uncover personalized risk factors and treatment responses. Emerging evidence suggests that genetic polymorphisms regulating calcium and oxalate metabolism, together with gut microbiota composition, significantly influence stone formation and recurrence. Advanced computational modeling and artificial intelligence can be utilized to predict stone risk based on metabolic signatures and lifestyle parameters, enabling proactive prevention strategies. Moreover, nanotechnology-based drug delivery systems and bioengineered inhibitors of crystal aggregation represent promising frontiers in targeted therapy. Integrating these innovations with long-term cohort studies

will enhance the understanding of nephrolithiasis as a systemic metabolic disorder rather than a localized renal disease, paving the way for individualized diagnostics and sustainable therapeutic outcomes.

REFERENCES

Aggarwal KP, Narula S, Kakkar M, Tandon C. Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int. 2013;2013(1):292953.

Ang AJS, Sharma AA, Sharma A. Nephrolithiasis: Approach to Diagnosis and Management. Indian J Pediatr. 2020;87(9):716-725.

Borghi L, Meschi T, Schianchi T, et al. Treatment of Nephrolithiasis in Medical Practice. Endocrinol Metab Clin North Am. 2002;30(3):729-732.

Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. Nat Rev Urol. 2016;13(11):654-662.

Fink HA, Akornor JW, Garimella PS, et al. Diet, Fluid, or Supplements for Secondary Prevention of Nephrolithiasis: A Systematic Review and Meta-Analysis of Randomized Trials. Eur Urol. 2009;56(1):72-80.

Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med. 2013;158(7):535-543.

Hall PM. Nephrolithiasis: Treatment, causes, and prevention. Cleve Clin J Med. 2009;76(10):583-591.

Kazim SM. Medical management of "haematemesis." Med Surg. 1978;18(6-7).

Lotan Y, Jiménez IB, Lenoir-Wijnkoop I, et al. Primary prevention of nephrolithiasis is costeffective for a national healthcare system. BJU Int. 2012;110(11 C):1-8.

Leroy J. the Current Diagnosis and Therapy of Nephrollthiasis. 1994.

Leslie SW, Sajjad H, Murphy PB. Renal calculi, nephrolithiasis. In: *StatPearls [Internet]*. StatPearls Publishing; 2024.

Moe OW, Abate N, Sakhaee K. Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):895-914.

Moore JP, Mauler DJ, Narang GL, Stern KL, Humphreys MR, Keddis MT. Etiology, urine metabolic risk factors, and urine oxalate patterns in patients with significant hyperoxaluria and recurrent nephrolithiasis. Int Urol Nephrol. 2022;54(11):2819-2825.

Paliouras C, Tsampikaki E, Alivanis P, Aperis G. Pathophysiology of Nephrolithiasis. Nephrol Res Rev. 2012;4(2):58-65.

Pak CYC. Medical management of nephrolithiasis. J Urol. 1982;128(6):1157-1164.

Pearle MS. Prevention of nephrolithiasis. Curr Opin Nephrol Hypertens. 2001;10(2):203-209.

Shastri S, Patel J, Sambandam KK, Lederer ED. Kidney stone pathophysiology, evaluation and management: core curriculum 2023. Am J kidney Dis. 2023;82(5):617-634.

Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: a systemic metabolic disorder. Clin Rev Bone Miner Metab. 2011;9(3):207-217.